Apnimed
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -43.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 3.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 4.1x | Better than 98% |
| Price / Sales | 6.1x | Better than 18% |
| P/E vs own 5-yr range | 35th pctl | Better than 72% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 82.6% | Better than 92% |
| Operating margin | -139.9% | Better than 7% |
| Net margin | -2.4% | Better than 22% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -42.6% | Better than 9% |
| Distance below 52-week high | 54.4% | Better than 15% |
Financial Health F
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 0.4x | Better than 1% |
| Debt to assets | 57.0% | Better than 10% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 212.8% | Better than 95% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 17.25
- Open
- 17.08
- Day range
- 15.95 - 17.73
- Avg price
- 16.34
- Volume
- 248.59K
- Turnover
- 4.06M
- Turnover ratei
- 2.07%
- Volume ratioi
- 0.68
- Amplitudei
- 10.30%
- 52-week rangei
- 13.88 - 35.29
Valuation
- P/Ei
- -5.00
- P/E (TTM)i
- 4.13
- P/Bi
- 2.35
- EPSi
- -3.22
- Book value / shi
- 6.84
- Net profit
- -134.01M
- Net assets
- 284.75M
Share structure
- Market cap
- 669.84M
- Float capi
- 193.08M
- Shares out
- 41.63M
- Float sharesi
- 12.00M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-07-31
54.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.58M net over the window
Short interest
- Shares short
- 1.59M
- % of floati
- 3.81%
- Days to coveri
- 4.54
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Apnimed (APMD)?
Apnimed last traded at 16.09. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Apnimed's market cap?
About 669.84M.
What is the P/E ratio of Apnimed?
The trailing twelve-month P/E is 4.13. The Valuation tab shows it against the stock's own five-year range.
Does Apnimed pay a dividend?
Apnimed does not currently pay a regular dividend.
Is Apnimed a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 50.33, which implies 212.8% upside from the current price. This is not investment advice.
What is Apnimed's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Apnimed a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Apnimed discussion 0 comments